Adelphi Trust Co Takes $921,000 Position in Thermo Fisher Scientific Inc. $TMO

Adelphi Trust Co bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,589 shares of the medical research company’s stock, valued at approximately $921,000.

A number of other hedge funds also recently added to or reduced their stakes in the company. Border to Coast Pensions Partnership Ltd raised its stake in Thermo Fisher Scientific by 17.8% during the 4th quarter. Border to Coast Pensions Partnership Ltd now owns 200,442 shares of the medical research company’s stock valued at $116,358,000 after buying an additional 30,245 shares during the last quarter. PFG Investments LLC raised its stake in Thermo Fisher Scientific by 24.6% during the 4th quarter. PFG Investments LLC now owns 2,732 shares of the medical research company’s stock valued at $1,583,000 after buying an additional 540 shares during the last quarter. Valmark Advisers Inc. raised its stake in Thermo Fisher Scientific by 7.6% during the 4th quarter. Valmark Advisers Inc. now owns 1,079 shares of the medical research company’s stock valued at $625,000 after buying an additional 76 shares during the last quarter. Annex Advisory Services LLC raised its stake in Thermo Fisher Scientific by 19.7% during the 4th quarter. Annex Advisory Services LLC now owns 21,089 shares of the medical research company’s stock valued at $12,220,000 after buying an additional 3,469 shares during the last quarter. Finally, BCS Wealth Management bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $282,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 0.8%

Shares of TMO stock opened at $531.69 on Thursday. The stock has a market cap of $197.59 billion, a P/E ratio of 29.97, a PEG ratio of 2.82 and a beta of 0.97. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The company has a quick ratio of 1.53, a current ratio of 1.89 and a debt-to-equity ratio of 0.67. The company’s fifty day simple moving average is $502.46 and its two-hundred day simple moving average is $550.12.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping the consensus estimate of $6.45 by $0.12. The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.10 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were given a dividend of $0.47 per share. The ex-dividend date was Friday, March 13th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio is currently 10.60%.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the sale, the executive vice president directly owned 20,752 shares in the company, valued at approximately $11,230,982.40. This represents a 1.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.33% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on TMO shares. Stifel Nicolaus boosted their price objective on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. TD Cowen cut their price objective on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research report on Friday, January 30th. Finally, Wells Fargo & Company set a $683.00 target price on shares of Thermo Fisher Scientific in a report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $631.25.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.